2,4-dinitrophenol has been researched along with Fatty Liver in 4 studies
2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed)
dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.
2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We examined whether a functionally liver-targeted derivative of 2,4-dinitrophenol (DNP), DNP-methyl ether (DNPME), could safely decrease hypertriglyceridemia, NAFLD, and insulin resistance without systemic toxicities." | 3.79 | Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. ( Cline, GW; Jurczak, MJ; Kim, T; Lee, HY; Perry, RJ; Pesta, D; Popov, VB; Rahimi, Y; Shulman, GI; Spiegel, DA; Zhang, D; Zhang, XM, 2013) |
| "Juvenile visceral steatosis (JVS) mice, which show systemic L-carnitine deficiency, may be an animal model of Reye's syndrome because of its phenotype of fat deposition and mitochondrial abnormalities in the liver." | 1.30 | Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. ( Hashimoto, N; Hayakawa, J; Higashi, Y; Miyamoto, K; Nezu, J; Nikaido, H; Nomura, M; Ohashi, R; Oku, A; Shimane, M; Tamai, I; Tatsumi, Y; Tsuji, A; Yokogawa, K; Yonekawa, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tingle, SJ | 1 |
| Thompson, ER | 1 |
| Bates, L | 1 |
| Ibrahim, IK | 1 |
| Govaere, O | 1 |
| Shuttleworth, V | 1 |
| Wang, L | 1 |
| Figueiredo, R | 1 |
| Palmer, J | 1 |
| Bury, Y | 1 |
| Anstee, QM | 1 |
| Wilson, C | 1 |
| Perry, RJ | 2 |
| Kim, T | 1 |
| Zhang, XM | 1 |
| Lee, HY | 1 |
| Pesta, D | 1 |
| Popov, VB | 1 |
| Zhang, D | 1 |
| Rahimi, Y | 1 |
| Jurczak, MJ | 1 |
| Cline, GW | 1 |
| Spiegel, DA | 1 |
| Shulman, GI | 2 |
| Yokogawa, K | 1 |
| Yonekawa, M | 1 |
| Tamai, I | 1 |
| Ohashi, R | 1 |
| Tatsumi, Y | 1 |
| Higashi, Y | 1 |
| Nomura, M | 1 |
| Hashimoto, N | 1 |
| Nikaido, H | 1 |
| Hayakawa, J | 1 |
| Nezu, J | 1 |
| Oku, A | 1 |
| Shimane, M | 1 |
| Miyamoto, K | 1 |
| Tsuji, A | 1 |
4 other studies available for 2,4-dinitrophenol and Fatty Liver
| Article | Year |
|---|---|
Pharmacological testing of therapeutics using normothermic machine perfusion: A pilot study of 2,4-dinitrophenol delivery to steatotic human livers.
Topics: 2,4-Dinitrophenol; Fatty Liver; Humans; Liver Transplantation; Organ Preservation; Perfusion; Pilot | 2022 |
Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler.
Topics: 2,4-Dinitrophenol; Animals; Diet, High-Fat; Ethers; Fatty Liver; Hypertriglyceridemia; Insulin Resis | 2013 |
Treating fatty liver and insulin resistance.
Topics: 2,4-Dinitrophenol; Animals; Fatty Liver; Insulin Resistance | 2013 |
Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice.
Topics: 2,4-Dinitrophenol; Animals; Anions; Biological Transport; Carnitine; Carrier Proteins; Cations; Fatt | 1999 |